KRAS and lung carcinoma: These results indicate that treatment with verteporfin and YAP1 knockdown have some similar effects on YAP1 signaling pathways but also exhibit clear differences that might contribute to the cytotoxicity of verteporfin in KRAS-mutant lung cancer cells.